Literature DB >> 19625268

The influence of COX-2 single nucleotide polymorphisms on abdominal aortic aneurysm development and the associated inflammation.

Stephen A Badger1, Chee V Soong, Ian S Young, Ann McGinty, Caroline Mercer, Anneq E Hughes.   

Abstract

INTRODUCTION: Cyclooxygenase (COX)-2 influences cardiovascular disease and serum concentration of high-sensitivity C-reactive protein (hsCRP). The study purpose was to determine the influence of single nucleotide polymorphisms (SNPs) of the COX-2 gene on abdominal aortic aneurysm (AAA) development and serum hsCRP concentrations. PATIENTS AND METHODS: Patients with AAA and disease-free controls were recruited. High-sensitivity C-reactive protein was measured by an enzyme-linked immunosorbent assay (ELISA) test. The distributions of COX-2 SNPs were investigated (rs20417 and rs4648307). The influence of the COX-2 SNPs on the hsCRP serum concentration was assessed.
RESULTS: A total of 230 patients with AAA and 279 controls were included. No difference was found in the genotype distribution of the COX-2 SNPs rs20417 (P = .26) and rs4648307 (P = .90). They did not influence the hsCRP concentration (P = .24 and P = .61, respectively). Haplotype analysis of COX-2 SNPs revealed no difference.
CONCLUSION: These COX-2 SNPs do not play any role in AAA development and do not influence serum hsCRP. These results differentiate AAA development from atherosclerotic diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625268     DOI: 10.1177/0003319709335027

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

Review 1.  Genes and abdominal aortic aneurysm.

Authors:  Irene Hinterseher; Gerard Tromp; Helena Kuivaniemi
Journal:  Ann Vasc Surg       Date:  2010-12-13       Impact factor: 1.466

2.  PharmGKB summary: very important pharmacogene information for PTGS2.

Authors:  Caroline F Thorn; Tilo Grosser; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.